

Annals of Oncology

[About This Journal](#) [Contact This Journal](#) [Subscriptions](#) [View Current Issue \(Volume 22 Issue 5 May 2011\)](#) [Archive](#) [Search](#)[Oxford Journals](#) [Medicine](#) [Annals of Oncology](#) [Advance Access](#) 10.1093/annonc/mdq727

Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial

T. D. Brisbois¹, I. H. de Kock², S. M. Watanabe², M. Mirhosseini², D. C. Lamoureux², M. Chasen³, N. MacDonald⁴, V. E. Baracos² and W. V. Wismer^{1,*}

[± Author Affiliations](#)

1. *¹Department of Agricultural, Food & Nutritional Science*
2. *²Division of Palliative Care Medicine, Department of Oncology, University of Alberta, Edmonton*
3. *³Division of Palliative Care Medicine, Department of Oncology, University of Ottawa, Ottawa*
4. *⁴Cancer Nutrition and Rehabilitation Program, Department of Oncology, McGill University, Montreal, Canada*

1. *Correspondence to: Dr. W. Wismer, Department of Agricultural, Food and Nutritional Science, 4-10 Ag/For Centre, University of Alberta, Edmonton, Alberta, Canada T6G 2P5. Tel: +780-492-2923; Fax: +780-492-4265; E-mail: wendy.wismer@ualberta.ca

- Received August 10, 2010.
- Revision received November 8, 2010.
- Accepted November 15, 2010.

Abstract

Background: A pilot study ([NCT00316563](#)) to determine if delta-9-tetrahydrocannabinol (THC) can improve taste and smell (chemosensory) perception as well as appetite, caloric intake, and quality of life (QOL) for cancer patients with chemosensory alterations.

Patients and methods: Adult advanced cancer patients, with poor appetite and chemosensory alterations, were recruited from two sites and randomized in a double-blinded manner to receive either THC (2.5 mg, Marinol®; Solvay Pharma Inc., $n = 24$) or placebo oral capsules ($n = 22$) twice daily for 18 days. Twenty-one patients completed the trial. At baseline and posttreatment, patients completed a panel of patient-reported outcomes: Taste and Smell Survey, 3-day food record, appetite and macronutrient preference assessments, QOL questionnaire, and an interview.

Results: THC and placebo groups were comparable at baseline. Compared with placebo, THC-treated patients reported improved ($P = 0.026$) and enhanced ($P < 0.001$) chemosensory perception and food ‘tasted better’ ($P = 0.04$). Premeal appetite ($P = 0.05$) and proportion of calories consumed as protein increased compared with placebo ($P = 0.008$). THC-treated patients reported increased quality of sleep ($P = 0.025$) and relaxation ($P = 0.045$). QOL scores and total caloric intake were improved in both THC and placebo groups.

Conclusions: THC may be useful in the palliation of chemosensory alterations and to improve food enjoyment for cancer patients.

Key words [anorexia/drug therapy](#) [appetite/drug effects](#), [neoplasms/complications](#) [taste/olfaction disorders/diagnosis](#) [tetrahydrocannabinol/therapeutic use](#)

- © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

This Article

Ann Oncol (2011) doi: 10.1093/annonc/mdq727 First published online: February 22, 2011

- » Abstract Free
- [Full Text \(HTML\)](#) Free
- [Full Text \(PDF\)](#) Free

- Classifications

- [Original article](#)

- Services

- [Alert me when cited](#)
- [Alert me if corrected](#)
- [Alert me if commented](#)
- [Find similar articles](#)
- [Similar articles in PubMed](#)
- [Add to my archive](#)
- [Download citation](#)
- [Request Permissions](#)
- [Disclaimer](#)

+ Responses

+ Citing Articles

+ Google Scholar

1. [Articles by Brisbois, T. D.](#)
2. [Articles by Wismer, W. V.](#)

+ PubMed

1. [PubMed citation](#)
2. [Articles by Brisbois, T. D.](#)
3. [Articles by Wismer, W. V.](#)

+ Related Content

+ Share